What are the uses of Vemurafenib

An orally bioavailable inhibitor, ATP-competitive small molecule BRAF (V600E) kinase with antineoplastic activity potential. Vemurafenib selectively binds to the ATP binding site of BRAF (V600E) kinase and inhibits its activity, which leads to an inhibition of more activated MAPK pathway downstream of BRAF (V600E) kinase can lead expressing tumor cells and a reduction in the proliferation of tumor cells. About 90% of BRAF mutations include valine for glutamic acid mutation at residue 600 (V600E); the product of the oncogene protein BRAF (V600E) kinase, present a significantly increased activity, over-active MAPK signaling pathway it. The BRAF (V600E) gene mutation has been found, enter about 60% of melanomas, and. In about 8% of all solid tumors, including melanoma, colon, thyroid and other cancers